Response to Pfirrmann et al.'s comment on How should we interpret conclusions of TKI-stopping studies

Leukemia. 2024 Feb;38(2):463-464. doi: 10.1038/s41375-023-02128-z. Epub 2023 Dec 27.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
  • Protein Kinase Inhibitors* / pharmacology
  • Protein Kinase Inhibitors* / therapeutic use

Substances

  • Protein Kinase Inhibitors